The US Food and Drug Administration (FDA) issued a warning today that the commonly prescribed breast cancer therapies known as cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors may cause rare but severe inflammation of the lungs. The related products include palbociclib (Ibrance, Pfizer), ribociclib (Kisqali, Novartis), and abemaciclib (Verzenio, Eli Lilly), which are approved for use in patients with hormone receptor (HR)-positive, human epidermal…
Author: GDPoster
Happy Onam
Happy Muharram….
Happy Teachers Day
FDA OKs Istradefylline for Parkinson’s Disease ‘Off’ Episodes
The US Food and Drug Administration (FDA) has approved istradefylline (Nourianz, Kyowa Kirin) tablets as add-on treatment to levodopa/carbidopa in adults with Parkinson’s disease (PD) experiencing “off” episodes. Istradefylline is a selective adenosine A2A receptor antagonist. Its effectiveness in treating “off” episodes in patients with PD taking levodopa/carbidopa was shown in four 12-week, placebo-controlled clinical studies that included a total of 1143 participants.…
Ganpati Bappa Moriya-Happy Ganesh Chaturthi
Exercise guidelines for cancer patients
There are no general guidelines about exercising after cancer. But several studies have shown that exercise is safe, possible and helpful for many people with cancer. Guidelines When you think about how different we all are and how many types of cancer and treatment there are, it’s difficult to write exercise guidelines to cover everyone. In…
Stage Set for Big Measles Outbreaks in Texas With Current Vaccination Rates
Current Texas schools’ vaccination rates could allow for measles outbreaks as large as 400 cases in the Dallas-Fort Worth and Austin metropolitan areas. Even slight decreases in immunization rates could result in exponentially larger outbreaks, the authors say, noting that other states have population centers at similar risk. “Lower vaccination rates imply that outbreaks may…
Happy Independence Day
FDA Approves Drug Trio for UTI, Intra-abdominal Infection
The US Food and Drug Administration (FDA) has approved the antibacterial drug trio imipenem, cilastatin, and relebactam (Recarbrio, Merck) for complicated urinary tract infection (cUTI) and complicated intra-abdominal infection (cIAI) in adults for whom “limited or no treatment options are available.” “Recarbrio provides an important addition to our toolkit in the ongoing fight against infections caused…
